We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Next Gen Digital Colposcope with AI Capabilities Redefines Cervical Cancer Screening

By HospiMedica International staff writers
Posted on 10 May 2023
Print article
Image: The EVAPro next gen digital colposcope is redefining cervical examination (Photo courtesy of MobileODT)
Image: The EVAPro next gen digital colposcope is redefining cervical examination (Photo courtesy of MobileODT)

Cervical cancer ranks as the 4th most common cancer among women globally. With over 300,000 women succumbing to cervical cancer annually, prompt follow-up and receiving immediate results at the point of care could be transformative. Now, an AI-powered digital mobile colposcope offers a screening alternative to the existing standard of care for cervical cancer, boasting significantly enhanced accuracy and speed – delivering results in under a minute.

MobileODT’s (Tel Aviv, Israel) EVAPro introduces the latest digital advancement in cervical cancer screening, improving the patient-physician experience. The next-gen EVAPro digital colposcope is lightweight and portable, offering exceptional image quality and advanced software capabilities. This unique combination enables physicians to document and monitor the entire treatment process and store it on the cloud. EVAPro-produced images are self-illuminating, enabling clearer image capture. Image assessment features a green filter to evaluate abnormal vessels and other landmarks or lesions. With autofocus, each image is assessed for multiple factors: cervix presence, illumination, cervix position, and image focus. Image-guided technology and ML allow image quality assessment, notifying the clinician that the image is suitable for visual inspection or colposcopic evaluation.

EVAPro employs AI and Machine Learning (ML) for large-scale cervical cancer screening. VisualCheck, an AI-based computer-aided diagnostic tool, operates on the EVAPro digital colposcope and evaluates the risk of dysplasia at the point of care. VisualCheck compares images captured during an exam with thousands of prior exams annotated by leading experts and histology results, predicting their classification. The algorithm is designed to recognize and identify CIN2+ based on data from 17 different countries. Clinical evaluation of VisualCheck reveals consistent agreement rates between VisualCheck scores and expert panels across three separate locations. VisualCheck is the only computer-aided diagnostic tool that evaluates the likelihood of cervical dysplasia, offering hope to women without direct access to specialists.

In addition to hosting the VisualCheck algorithm, the EVAPro digital colposcope provides various advanced features to support colposcopy. Fully portable and Wi-Fi enabled, EVAPro allows for instant consultation, either within the hospital or globally, while captured images can be uploaded and shared remotely. These images can be annotated for precise consultation by specialists in other locations. Consulting physicians can view the biopsy's real-time location and timing. For practitioners in remote or resource-limited areas, this can mean the difference between rapid diagnosis and treatment or a lengthy delay between testing and treatment. Furthermore, the system can be easily integrated into medical records, offering a visual record of an exam and a historical record useful for clinicians seeing the same patient in the future.

Related Links:

Platinum Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Multi-Parameter Patient Monitor
Lesion Tracking Application
Sectra Lesion Tracking
Electric Gynecological Operating Table

Print article
FIME - Informa



view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Surgical Techniques

view channel
Image: The deployable electrodes are ideal for minimally invasive craniosurgery (Photo courtesy of EPFL)

Soft Robotic Electrode Offers Minimally Invasive Solution for Craniosurgery

Minimally invasive medical procedures offer numerous benefits to patients, including decreased tissue damage and shorter recovery periods. However, creating equipment that can pass through a small opening... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis (Photo courtesy of Cytovale)

Rapid Microfluidic Test Demonstrates Efficacy as Diagnostic Aid to Improve Sepsis Triage in ED

Sepsis is the primary cause of mortality worldwide, accounting for over 350,000 fatalities annually in the United States alone, a figure that surpasses deaths from opioid overdoses, prostate cancer, and... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.